Acetyl 2-[3-(2-acetyloxycarbonylphenoxy)propoxy]benzoate | 221291-99-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Acetyl 2-[3-(2-acetyloxycarbonylphenoxy)propoxy]benzoate
• CAS: 221291-99-2
• 化学式: C₂₁H₂₀O₈
• 分子量: 400.385
• InChiKey: BVYGASIIJRPLOM-UHFFFAOYSA-N

物化性质

• 沸点：
  593.5±50.0 °C(Predicted)
• 密度：
  1.259±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  29
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1,3-bis(carboxyphenoxy)propane 、 乙酸酐 生成 Acetyl 2-[3-(2-acetyloxycarbonylphenoxy)propoxy]benzoate
  参考文献：
  名称：

  WO2008/51565

  摘要：

  公开号：

文献信息

• Drug delivery polyanhydride composition and method
  申请人：Hnojewyj Olexander

  公开号：US20080014170A1

  公开（公告）日：2008-01-17

  The disclosure is generally directed to a biodegradable polymer composition comprising a drug-containing polymer component having a backbone containing one or more therapeutic drugs that are linked together by anhydride linkages, such that molecules of the drug are released upon biodegradation of the component. The biodegradable polymer composition also comprises a polyester-based polymer component.

  该披露通常涉及一种生物降解聚合物组合物，包括具有主干的含药聚合物组分，该主干含有一个或多个治疗药物，这些药物通过酸酐键连接在一起，从而在组分生物降解时释放药物分子。该生物降解聚合物组合物还包括一种基于聚酯的聚合物组分。
• Polyanhydride polymers and their uses in biomedical devices
  申请人：Varshney K. Sunil

  公开号：US20070225472A1

  公开（公告）日：2007-09-27

  A biocompatible, bioerodable polyanhydride polymer having a Young's modulus between about 1.5 and 3 and a selected rate of surface degradation, and methods of forming and using the polymer, are disclosed. The polymer is formed of a polyester prepolymer having a preferred molecular weight of greater than 5 and less than 7.5 Kdaltons, and a selected number of anhydride linkages between 5 and about 30.
• DRUG-RELEASE COMPOSITION HAVING A THERAPEUTIC CARRIER
  申请人：Hnojewyj Olexander

  公开号：US20110223232A1

  公开（公告）日：2011-09-15

  The invention is generally directed to a drug-release composition that contains drug-linker-drug compound that is combined with another therapeutic agent that can be an antirestenotic agent. The therapeutic agent can be partially bound to the drug-linker-drug compound, miscible with the drug-linker-drug compound, combined with the drug-linker-drug compound at various ratios, and tuned to control the release of drugs to a tissue in need thereof.